Wikipedia -WSS

Wikipedia

author：focus 2025-10-01 23:39:47 - browse：514

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.

Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.

Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Hospitals consider fixing cancer drug shortages on their own

WSS

Vertex Pharmaceuticals may move headquarters in Boston

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Food as medicine: Medically tailored meals may get standardized

Roche subsidiary Foundation Medicine opens new headquarters

Oprah kicked off a national conversation on obesity. Let's have it

Oprah kicked off a national conversation on obesity. Let's have it

focus

Wikipedia

focus

Wildfire smoke exposes gaps in outdoor worker protections

Scientists boost immune system in aging mice by making it youthful

Medicare details structure of new drug price negotiation program

Diverse clinical trials: Why aren’t we there yet?

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

How to make the FDA’s new prescription one

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

As demand for Covid shots wanes, Moderna seeks its next success

Walmart eyes Medicare Advantage provider ChenMed

explore

How medical schools plan to diversify without affirmative action

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

FDA's naming rule on biosimilars has undermined competition

Will the IRA bring competition to the biologics market?

Readout Newsletter: Merck, Vertex, and Viking updates

Oprah kicked off a national conversation on obesity. Let's have it

hotspot

Wikipedia

focus

focus